The molecular diagnostic complements the company’s HPV blood test.
Grant Life Sciences has licensed the manufacturing and marketing rights to Alphagenics Diaco Biotechnologies’ molecular diagnostic test for HPVs. This HPV test is a DNA-based molecular diagnostic that uses standard equipment found in most commercial laboratories.
The Memo of Understanding between the companies gives Grant Life Sciences exclusive rights in Greater China and the U.S. and nonexclusive rights in Europe, India, Australia, and Japan.
Alphagenics’ HPV DNA test complements the HPV blood test that Grant Life Sciences has been developing. The blood test is a serum-based immunological test to detect cervical dysplasia.
While a serum-based test to detect precancerous evidence and cancer of the cervix is still viewed by Grant Life Sciences as the preferred test-methodology to address the needs of the developing world, molecular testing is currently the approved test protocol in both the U.S. and Europe. Grant expects to launch the Alphagenics HPV DNA-based test in the Asian and Indian markets during the fourth quarter of this year.
